Viridian Therapeutics, Inc.\DE — Income Charts
2 years of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue
$71M
Cost of Revenue
—
R&D
$339M
SG&A
$95M
D&A
$460K
Operating Income
$-363M
EBITDA
$-363M
Interest Expense
$5M
Interest Income
$27M
Tax Provision
$0
Net Income
$-343M
Operating Margin
-512.9%
Net Margin
-483.6%
Deferred Tax Assets
$0
Deferred Tax Liabilities
—
DTA Valuation Allowance
$317M
Tax Credit Carryforwards
$28M
NOL Carryforwards
$124M
ETR (Continuing Operations)
0.0%
ETR Federal Statutory
21.0%
ETR State + Local (pp)
5.0%
Operating Lease Cost
—
Revenue YoY Variation
23359.9%
Income YoY Variation
-21.5%